Chemomab Therapeutics Ltd. — Net Income by Fiscal Year
8 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/11bd4852-efac-48e0-9bfd-80c2dc716af0/serie/net-income
| Fiscal year | Net Income | Period | Evidence |
|---|---|---|---|
| FY 2025 | $-9.0M | 2025-01-01 – 2025-12-31 | evidence 0001178913-26-001593 |
| FY 2024 | $-13.9M | 2024-01-01 – 2024-12-31 | evidence 0001178913-25-001205 |
| FY 2023 | $-24.2M | 2023-01-01 – 2023-12-31 | evidence 0001178913-24-001124 |
| FY 2022 | $-27.6M | 2022-01-01 – 2022-12-31 | evidence 0001178913-23-000670 |
| FY 2021 | $-12.5M | 2021-01-01 – 2021-12-31 | evidence 0001178913-22-001304 |
| FY 2020 | $-6.0M | 2020-01-01 – 2020-12-31 | evidence 0001178913-22-001304 |
| FY 2019 | $-27.1M | 2019-01-01 – 2019-12-31 | evidence 0001104659-20-034835 |
| FY 2018 | $-13.8M | 2018-01-01 – 2018-12-31 | evidence 0001104659-20-034835 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).